chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 74.0
Sex: M
Vaccine: VARZOS, VARZOS
Symptoms: Brain oedema, Herpes zoster, Herpes zoster ophthalmic
Clinical narrative: Information has been received from a pharmacist concerning a 74 year old male patient with no pertinent medical history and no known drug  reactions/allergies who on 09-FEB-2010 was vaccinated with a 0.5 ml SQ dose of ZOSTAVAX (Merck) (lot# 665311/1310Y). There was no concomitant medication. On 18-FEB-2010 the patient saw his physician and was diagnosed with shingles. His shingles outbreak spread to his eye and then to his brain. It was reported that the patient experienced brain swelling. The patient was hospitalized. At the time of the report, the patient had not recovered. The reporting pharmacist considered "shingles outbreak spread to his brain", "shingles outbreak spread to his eye" and "brain swelling" to be immediately life-threatening. A lot check has been initiated. Additional information has been requested. Hospital name was unknown.
Age: 22.0
Sex: M
Vaccine: HPV4, HPV4
Symptoms: Erythema, Rash macular
Clinical narrative: Receive her first GARDASIL vaccination at 0930 on 9/30/2009. She reported history of sore throat, body aches, low grade fever, runny nose and non-specific malaise for approximately the three days preceding her vaccination for which she was using THERAFLU and throat lozenges. Symptoms had resolved by the time of vaccination. Approximately 20 minutes after receiving this shot while having her blood drawn, she noticed a small area of mildly pruritic red raised bumps (pimple size) on her left forearm. She returned to clinic and was prescribed diphenhydramine 25 mg. About 12 hours later (@2230 hr) her face (jaw line) was puffy with welts and flushed. She had scattered red rash to both arms (upper/lower). She denied any throat swelling or pain, tightness, difficulty breathing or swallowing. No lip edema, no itching. No joint/muscle pain. She took her first BENADRYL (unsure if 1 or 2 caps taken), climbed into hot bathtub of water and fell asleep. She awoke about 5 am (10 hrs after vaccination) still in the bathtub and noticed a scattered red blotchy rash to chest, abdomen, back, buttock, arms, and legs. She again denied any diff breathing, lip edema, chest pain, or dysphagia. The "hives" appeared red and flat and were not pruritic. She did  c/o of feeling weak and tired, and of increased skin sensitivity/burning in area of hives. She denied any new detergents, soaps, deodorants, lotions, oils, hair products, etc. She denied any food allergies. She presented to local clinic, diagnosed with an "allergic reaction" and was treated with CYCLOCORT top lotion, oatmeal bath and prednisone (60 mg x 5d, 40 mg x 5d, 20 mg x5d). She only took one dose of BENADRYL and only 2 days of steroids before stopping as she saw no resolution of symptoms. She did note relief with CYCLOCORT and used x 2 weeks with full resolution of symptoms. She denied mucosal involvement at any time. The area of her rash remained hypopigmented with skin returning to normal color about 5 months later. The patient is known to be atopic. In March 2010 she was evaluated for a history of nasal congestion, discharge, and pruritus during the spring and fall months and anytime when lying on carpeting. Allergy testing was positive to most trees, grasses, weeds, cat, dog, dust, mite, and cockroach. She has a history of exercise induced asthma for which she takes albuterol prn. She was also diagnosed with oral allergy syndrome. When she had a fruit smoothie containing bananas/pineapples she felt like her throat was tight and couldn't take a deep breath in. This lasted 1 hour. she is able to eat bananas without problem but when she eats pineapples her lips "crack and bleed." Skin testing to banana and shrimp was negative. She has been prescribed ZYRTEC 10 mg daily.
Age: 22.0
Sex: M
Vaccine: HPV4, HPV4
Symptoms: Asthenia, Erythema, Fatigue, Flushing, Hypersensitivity
Clinical narrative: Receive her first GARDASIL vaccination at 0930 on 9/30/2009. She reported history of sore throat, body aches, low grade fever, runny nose and non-specific malaise for approximately the three days preceding her vaccination for which she was using THERAFLU and throat lozenges. Symptoms had resolved by the time of vaccination. Approximately 20 minutes after receiving this shot while having her blood drawn, she noticed a small area of mildly pruritic red raised bumps (pimple size) on her left forearm. She returned to clinic and was prescribed diphenhydramine 25 mg. About 12 hours later (@2230 hr) her face (jaw line) was puffy with welts and flushed. She had scattered red rash to both arms (upper/lower). She denied any throat swelling or pain, tightness, difficulty breathing or swallowing. No lip edema, no itching. No joint/muscle pain. She took her first BENADRYL (unsure if 1 or 2 caps taken), climbed into hot bathtub of water and fell asleep. She awoke about 5 am (10 hrs after vaccination) still in the bathtub and noticed a scattered red blotchy rash to chest, abdomen, back, buttock, arms, and legs. She again denied any diff breathing, lip edema, chest pain, or dysphagia. The "hives" appeared red and flat and were not pruritic. She did  c/o of feeling weak and tired, and of increased skin sensitivity/burning in area of hives. She denied any new detergents, soaps, deodorants, lotions, oils, hair products, etc. She denied any food allergies. She presented to local clinic, diagnosed with an "allergic reaction" and was treated with CYCLOCORT top lotion, oatmeal bath and prednisone (60 mg x 5d, 40 mg x 5d, 20 mg x5d). She only took one dose of BENADRYL and only 2 days of steroids before stopping as she saw no resolution of symptoms. She did note relief with CYCLOCORT and used x 2 weeks with full resolution of symptoms. She denied mucosal involvement at any time. The area of her rash remained hypopigmented with skin returning to normal color about 5 months later. The patient is known to be atopic. In March 2010 she was evaluated for a history of nasal congestion, discharge, and pruritus during the spring and fall months and anytime when lying on carpeting. Allergy testing was positive to most trees, grasses, weeds, cat, dog, dust, mite, and cockroach. She has a history of exercise induced asthma for which she takes albuterol prn. She was also diagnosed with oral allergy syndrome. When she had a fruit smoothie containing bananas/pineapples she felt like her throat was tight and couldn't take a deep breath in. This lasted 1 hour. she is able to eat bananas without problem but when she eats pineapples her lips "crack and bleed." Skin testing to banana and shrimp was negative. She has been prescribed ZYRTEC 10 mg daily.
Age: 22.0
Sex: M
Vaccine: HPV4, HPV4
Symptoms: Oral allergy syndrome, Rash macular, Rash papular, Rash pruritic, Skin burning sensation
Clinical narrative: Receive her first GARDASIL vaccination at 0930 on 9/30/2009. She reported history of sore throat, body aches, low grade fever, runny nose and non-specific malaise for approximately the three days preceding her vaccination for which she was using THERAFLU and throat lozenges. Symptoms had resolved by the time of vaccination. Approximately 20 minutes after receiving this shot while having her blood drawn, she noticed a small area of mildly pruritic red raised bumps (pimple size) on her left forearm. She returned to clinic and was prescribed diphenhydramine 25 mg. About 12 hours later (@2230 hr) her face (jaw line) was puffy with welts and flushed. She had scattered red rash to both arms (upper/lower). She denied any throat swelling or pain, tightness, difficulty breathing or swallowing. No lip edema, no itching. No joint/muscle pain. She took her first BENADRYL (unsure if 1 or 2 caps taken), climbed into hot bathtub of water and fell asleep. She awoke about 5 am (10 hrs after vaccination) still in the bathtub and noticed a scattered red blotchy rash to chest, abdomen, back, buttock, arms, and legs. She again denied any diff breathing, lip edema, chest pain, or dysphagia. The "hives" appeared red and flat and were not pruritic. She did  c/o of feeling weak and tired, and of increased skin sensitivity/burning in area of hives. She denied any new detergents, soaps, deodorants, lotions, oils, hair products, etc. She denied any food allergies. She presented to local clinic, diagnosed with an "allergic reaction" and was treated with CYCLOCORT top lotion, oatmeal bath and prednisone (60 mg x 5d, 40 mg x 5d, 20 mg x5d). She only took one dose of BENADRYL and only 2 days of steroids before stopping as she saw no resolution of symptoms. She did note relief with CYCLOCORT and used x 2 weeks with full resolution of symptoms. She denied mucosal involvement at any time. The area of her rash remained hypopigmented with skin returning to normal color about 5 months later. The patient is known to be atopic. In March 2010 she was evaluated for a history of nasal congestion, discharge, and pruritus during the spring and fall months and anytime when lying on carpeting. Allergy testing was positive to most trees, grasses, weeds, cat, dog, dust, mite, and cockroach. She has a history of exercise induced asthma for which she takes albuterol prn. She was also diagnosed with oral allergy syndrome. When she had a fruit smoothie containing bananas/pineapples she felt like her throat was tight and couldn't take a deep breath in. This lasted 1 hour. she is able to eat bananas without problem but when she eats pineapples her lips "crack and bleed." Skin testing to banana and shrimp was negative. She has been prescribed ZYRTEC 10 mg daily.
Age: 22.0
Sex: M
Vaccine: HPV4, HPV4
Symptoms: Skin test positive, Swelling face, Urticaria
Clinical narrative: Receive her first GARDASIL vaccination at 0930 on 9/30/2009. She reported history of sore throat, body aches, low grade fever, runny nose and non-specific malaise for approximately the three days preceding her vaccination for which she was using THERAFLU and throat lozenges. Symptoms had resolved by the time of vaccination. Approximately 20 minutes after receiving this shot while having her blood drawn, she noticed a small area of mildly pruritic red raised bumps (pimple size) on her left forearm. She returned to clinic and was prescribed diphenhydramine 25 mg. About 12 hours later (@2230 hr) her face (jaw line) was puffy with welts and flushed. She had scattered red rash to both arms (upper/lower). She denied any throat swelling or pain, tightness, difficulty breathing or swallowing. No lip edema, no itching. No joint/muscle pain. She took her first BENADRYL (unsure if 1 or 2 caps taken), climbed into hot bathtub of water and fell asleep. She awoke about 5 am (10 hrs after vaccination) still in the bathtub and noticed a scattered red blotchy rash to chest, abdomen, back, buttock, arms, and legs. She again denied any diff breathing, lip edema, chest pain, or dysphagia. The "hives" appeared red and flat and were not pruritic. She did  c/o of feeling weak and tired, and of increased skin sensitivity/burning in area of hives. She denied any new detergents, soaps, deodorants, lotions, oils, hair products, etc. She denied any food allergies. She presented to local clinic, diagnosed with an "allergic reaction" and was treated with CYCLOCORT top lotion, oatmeal bath and prednisone (60 mg x 5d, 40 mg x 5d, 20 mg x5d). She only took one dose of BENADRYL and only 2 days of steroids before stopping as she saw no resolution of symptoms. She did note relief with CYCLOCORT and used x 2 weeks with full resolution of symptoms. She denied mucosal involvement at any time. The area of her rash remained hypopigmented with skin returning to normal color about 5 months later. The patient is known to be atopic. In March 2010 she was evaluated for a history of nasal congestion, discharge, and pruritus during the spring and fall months and anytime when lying on carpeting. Allergy testing was positive to most trees, grasses, weeds, cat, dog, dust, mite, and cockroach. She has a history of exercise induced asthma for which she takes albuterol prn. She was also diagnosed with oral allergy syndrome. When she had a fruit smoothie containing bananas/pineapples she felt like her throat was tight and couldn't take a deep breath in. This lasted 1 hour. she is able to eat bananas without problem but when she eats pineapples her lips "crack and bleed." Skin testing to banana and shrimp was negative. She has been prescribed ZYRTEC 10 mg daily.
Age: 0.3
Sex: M
Vaccine: DTAPIPVHIB, PNC, RV1, DTAPIPVHIB, PNC, RV1
Symptoms: Diarrhoea, Irritability, Ultrasound abdomen, X-ray with contrast upper gastrointestinal tract
Clinical narrative: This case was reported by a physician via sales representative and described the occurrence of abdominal cramp in a 4-month-old male subject who was vaccinated with ROTARIX (GlaxoSmithKline). Previous and/or concurrent vaccination included PENTACEL (non-gsk); non-GSK manufacturer; unknown; unknown given in February 2010; PREVNAR (non-gsk); non-GSK manufacturer; unknown; unknown given in February 2010. On an unspecified date in February 2010 the subject received 2nd dose of ROTARIX (oral). On an unspecified date, 24 hours after vaccination with ROTARIX, the subject experienced abdominal cramp. The 4-month old subject received his second ROTARIX dose in February 2010 and developed severe abdominal cramping. The cramping was intermittent and resolved after one month. The child was hospitalized for a few days and underwent several tests without any clear reason for the cramping. The subject was hospitalised. On an unspecified date in 2010, the abdominal cramping was resolved.
Age: 0.3
Sex: M
Vaccine: DTAPIPVHIB, PNC, RV1, DTAPIPVHIB, PNC, RV1
Symptoms: Abdominal pain
Clinical narrative: This case was reported by a physician via sales representative and described the occurrence of abdominal cramp in a 4-month-old male subject who was vaccinated with ROTARIX (GlaxoSmithKline). Previous and/or concurrent vaccination included PENTACEL (non-gsk); non-GSK manufacturer; unknown; unknown given in February 2010; PREVNAR (non-gsk); non-GSK manufacturer; unknown; unknown given in February 2010. On an unspecified date in February 2010 the subject received 2nd dose of ROTARIX (oral). On an unspecified date, 24 hours after vaccination with ROTARIX, the subject experienced abdominal cramp. The 4-month old subject received his second ROTARIX dose in February 2010 and developed severe abdominal cramping. The cramping was intermittent and resolved after one month. The child was hospitalized for a few days and underwent several tests without any clear reason for the cramping. The subject was hospitalised. On an unspecified date in 2010, the abdominal cramping was resolved.
Age: 1.0
Sex: F
Vaccine: DTAP, HIBV, MMR, PPV, DTAP
Symptoms: Biopsy skin abnormal, Blood culture negative, Blood test normal, CSF culture negative, Condition aggravated
Clinical narrative: Abstract: "We report a female infant with recurrent biopsy-proven vesicobullous incontinentia pigmenti occurring after her 12-month and 18-month immunizations. To our knowledge, incontinentia pigmenti vesicobullous recurrence following immunizations has not been reported. We propose that vaccinations may serve as triggers for incontinentia pigmenti reactivation." Initial report received on 12 April 2010 from an article. A 12 month old female infant with a history of incontinentia pigmenti with recurrent vesicobullous eruptions, received an injection of HIB vaccine (manufacturer and lot number not reported), an injection of MMR (manufacturer and lot number not reported) and an injection of PNEUMO vaccine (manufacturer and lot number not reported) on an unspecified date. One week after the vaccinations, vesicobullous lesions appeared within linear patches. There were no verrucous lesions, fever or other systemic complaints. Medical history indicated the onset of seizures and rash started simultaneously at day 3 of life and the patient was hospitalized at 5 days old. On an unspecified date, a biopsy and histopathology had revealed IP and genetic testing confirmed the diagnosis. Vesicobullous eruptions recurred at one month after hospitalization and four months of age. The patient's mother had reported no eruptions following vaccinations at 2, 4 and 6 months. Of note, at 18 months of age, the patient received an injection of DTaP (manufacturer and lot number not reported and 3 to 5 days post vaccination a similar eruption occurred in the same distribution (captured in case number 2010-02117). Also, between the 12 month and 18 month vaccinations the patient experienced two upper respiratory infections with fever, but without associated cutaneous eruptions. An ophthalmologic examination found no abnormalities. The reporters for this case are the same as for case 2010-02117. Documents held by sender: None.
Age: 1.0
Sex: F
Vaccine: DTAP, HIBV, MMR, PPV, DTAP
Symptoms: Congenital skin disorder, Convulsion, Culture urine negative, Dermatitis bullous, Electroencephalogram normal
Clinical narrative: Abstract: "We report a female infant with recurrent biopsy-proven vesicobullous incontinentia pigmenti occurring after her 12-month and 18-month immunizations. To our knowledge, incontinentia pigmenti vesicobullous recurrence following immunizations has not been reported. We propose that vaccinations may serve as triggers for incontinentia pigmenti reactivation." Initial report received on 12 April 2010 from an article. A 12 month old female infant with a history of incontinentia pigmenti with recurrent vesicobullous eruptions, received an injection of HIB vaccine (manufacturer and lot number not reported), an injection of MMR (manufacturer and lot number not reported) and an injection of PNEUMO vaccine (manufacturer and lot number not reported) on an unspecified date. One week after the vaccinations, vesicobullous lesions appeared within linear patches. There were no verrucous lesions, fever or other systemic complaints. Medical history indicated the onset of seizures and rash started simultaneously at day 3 of life and the patient was hospitalized at 5 days old. On an unspecified date, a biopsy and histopathology had revealed IP and genetic testing confirmed the diagnosis. Vesicobullous eruptions recurred at one month after hospitalization and four months of age. The patient's mother had reported no eruptions following vaccinations at 2, 4 and 6 months. Of note, at 18 months of age, the patient received an injection of DTaP (manufacturer and lot number not reported and 3 to 5 days post vaccination a similar eruption occurred in the same distribution (captured in case number 2010-02117). Also, between the 12 month and 18 month vaccinations the patient experienced two upper respiratory infections with fever, but without associated cutaneous eruptions. An ophthalmologic examination found no abnormalities. The reporters for this case are the same as for case 2010-02117. Documents held by sender: None.
Age: 1.0
Sex: F
Vaccine: DTAP, HIBV, MMR, PPV, DTAP
Symptoms: Erythema toxicum neonatorum, Herpes simplex serology negative, No reaction on previous exposure to drug, Pyrexia, Skin oedema
Clinical narrative: Abstract: "We report a female infant with recurrent biopsy-proven vesicobullous incontinentia pigmenti occurring after her 12-month and 18-month immunizations. To our knowledge, incontinentia pigmenti vesicobullous recurrence following immunizations has not been reported. We propose that vaccinations may serve as triggers for incontinentia pigmenti reactivation." Initial report received on 12 April 2010 from an article. A 12 month old female infant with a history of incontinentia pigmenti with recurrent vesicobullous eruptions, received an injection of HIB vaccine (manufacturer and lot number not reported), an injection of MMR (manufacturer and lot number not reported) and an injection of PNEUMO vaccine (manufacturer and lot number not reported) on an unspecified date. One week after the vaccinations, vesicobullous lesions appeared within linear patches. There were no verrucous lesions, fever or other systemic complaints. Medical history indicated the onset of seizures and rash started simultaneously at day 3 of life and the patient was hospitalized at 5 days old. On an unspecified date, a biopsy and histopathology had revealed IP and genetic testing confirmed the diagnosis. Vesicobullous eruptions recurred at one month after hospitalization and four months of age. The patient's mother had reported no eruptions following vaccinations at 2, 4 and 6 months. Of note, at 18 months of age, the patient received an injection of DTaP (manufacturer and lot number not reported and 3 to 5 days post vaccination a similar eruption occurred in the same distribution (captured in case number 2010-02117). Also, between the 12 month and 18 month vaccinations the patient experienced two upper respiratory infections with fever, but without associated cutaneous eruptions. An ophthalmologic examination found no abnormalities. The reporters for this case are the same as for case 2010-02117. Documents held by sender: None.
Age: 1.0
Sex: F
Vaccine: DTAP, HIBV, MMR, PPV, DTAP
Symptoms: Upper respiratory tract infection
Clinical narrative: Abstract: "We report a female infant with recurrent biopsy-proven vesicobullous incontinentia pigmenti occurring after her 12-month and 18-month immunizations. To our knowledge, incontinentia pigmenti vesicobullous recurrence following immunizations has not been reported. We propose that vaccinations may serve as triggers for incontinentia pigmenti reactivation." Initial report received on 12 April 2010 from an article. A 12 month old female infant with a history of incontinentia pigmenti with recurrent vesicobullous eruptions, received an injection of HIB vaccine (manufacturer and lot number not reported), an injection of MMR (manufacturer and lot number not reported) and an injection of PNEUMO vaccine (manufacturer and lot number not reported) on an unspecified date. One week after the vaccinations, vesicobullous lesions appeared within linear patches. There were no verrucous lesions, fever or other systemic complaints. Medical history indicated the onset of seizures and rash started simultaneously at day 3 of life and the patient was hospitalized at 5 days old. On an unspecified date, a biopsy and histopathology had revealed IP and genetic testing confirmed the diagnosis. Vesicobullous eruptions recurred at one month after hospitalization and four months of age. The patient's mother had reported no eruptions following vaccinations at 2, 4 and 6 months. Of note, at 18 months of age, the patient received an injection of DTaP (manufacturer and lot number not reported and 3 to 5 days post vaccination a similar eruption occurred in the same distribution (captured in case number 2010-02117). Also, between the 12 month and 18 month vaccinations the patient experienced two upper respiratory infections with fever, but without associated cutaneous eruptions. An ophthalmologic examination found no abnormalities. The reporters for this case are the same as for case 2010-02117. Documents held by sender: None.
Age: 1.0
Sex: F
Vaccine: DTAP, HIBV, MMR, PPV, DTAP
Symptoms: Biopsy, Dermatitis bullous, Gene mutation identification test positive, Histology abnormal, Inappropriate schedule of drug administration
Clinical narrative: Abstract: "We report a female infant with recurrent biopsy-proven vesicobullous incontinentia pigmenti occurring after her 12-month and 18-month immunizations. To our knowledge, incontinentia pigmenti vesicobullous recurrence following immunizations has not been reported. We propose that vaccinations may serve as triggers for incontinentia pigmenti reactivation." Initial report received on 12 April 2010 from an article. A 12 month old female infant with a history of incontinentia pigmenti with recurrent vesicobullous eruptions, received an injection of HIB vaccine (manufacturer and lot number not reported), an injection of MMR (manufacturer and lot number not reported) and an injection of PNEUMO vaccine (manufacturer and lot number not reported) on an unspecified date. One week after the vaccinations, vesicobullous lesions appeared within linear patches. There were no verrucous lesions, fever or other systemic complaints. Medical history indicated the onset of seizures and rash started simultaneously at day 3 of life and the patient was hospitalized at 5 days old. On an unspecified date, a biopsy and histopathology had revealed IP and genetic testing confirmed the diagnosis. Vesicobullous eruptions recurred at one month after hospitalization and four months of age. The patient's mother had reported no eruptions following vaccinations at 2, 4 and 6 months. Of note, at 18 months of age, the patient received an injection of DTaP (manufacturer and lot number not reported and 3 to 5 days post vaccination a similar eruption occurred in the same distribution (captured in case number 2010-02117). Also, between the 12 month and 18 month vaccinations the patient experienced two upper respiratory infections with fever, but without associated cutaneous eruptions. An ophthalmologic examination found no abnormalities. The reporters for this case are the same as for case 2010-02117. Documents held by sender: None.
Age: 1.0
Sex: F
Vaccine: DTAP, HIBV, MMR, PPV, DTAP
Symptoms: Interstitial lung disease, Pathology test, Pigmentation disorder, Pyrexia, Upper respiratory tract infection
Clinical narrative: Abstract: "We report a female infant with recurrent biopsy-proven vesicobullous incontinentia pigmenti occurring after her 12-month and 18-month immunizations. To our knowledge, incontinentia pigmenti vesicobullous recurrence following immunizations has not been reported. We propose that vaccinations may serve as triggers for incontinentia pigmenti reactivation." Initial report received on 12 April 2010 from an article. A 12 month old female infant with a history of incontinentia pigmenti with recurrent vesicobullous eruptions, received an injection of HIB vaccine (manufacturer and lot number not reported), an injection of MMR (manufacturer and lot number not reported) and an injection of PNEUMO vaccine (manufacturer and lot number not reported) on an unspecified date. One week after the vaccinations, vesicobullous lesions appeared within linear patches. There were no verrucous lesions, fever or other systemic complaints. Medical history indicated the onset of seizures and rash started simultaneously at day 3 of life and the patient was hospitalized at 5 days old. On an unspecified date, a biopsy and histopathology had revealed IP and genetic testing confirmed the diagnosis. Vesicobullous eruptions recurred at one month after hospitalization and four months of age. The patient's mother had reported no eruptions following vaccinations at 2, 4 and 6 months. Of note, at 18 months of age, the patient received an injection of DTaP (manufacturer and lot number not reported and 3 to 5 days post vaccination a similar eruption occurred in the same distribution (captured in case number 2010-02117). Also, between the 12 month and 18 month vaccinations the patient experienced two upper respiratory infections with fever, but without associated cutaneous eruptions. An ophthalmologic examination found no abnormalities. The reporters for this case are the same as for case 2010-02117. Documents held by sender: None.
Age: 1.0
Sex: F
Vaccine: DTAP, HIBV, MMR, PPV, DTAP
Symptoms: Biopsy skin abnormal, Dermatitis bullous, Erythema toxicum neonatorum, Gene mutation identification test positive, Laboratory test abnormal
Clinical narrative: Abstract: "We report a female infant with recurrent biopsy-proven vesicobullous incontinentia pigmenti occurring after her 12-month and 18-month immunizations. To our knowledge, incontinentia pigmenti vesicobullous recurrence following immunizations has not been reported. We propose that vaccinations may serve as triggers for incontinentia pigmenti reactivation." Initial report received on 12 April 2010 from an article. A 12 month old female infant with a history of incontinentia pigmenti with recurrent vesicobullous eruptions, received an injection of HIB vaccine (manufacturer and lot number not reported), an injection of MMR (manufacturer and lot number not reported) and an injection of PNEUMO vaccine (manufacturer and lot number not reported) on an unspecified date. One week after the vaccinations, vesicobullous lesions appeared within linear patches. There were no verrucous lesions, fever or other systemic complaints. Medical history indicated the onset of seizures and rash started simultaneously at day 3 of life and the patient was hospitalized at 5 days old. On an unspecified date, a biopsy and histopathology had revealed IP and genetic testing confirmed the diagnosis. Vesicobullous eruptions recurred at one month after hospitalization and four months of age. The patient's mother had reported no eruptions following vaccinations at 2, 4 and 6 months. Of note, at 18 months of age, the patient received an injection of DTaP (manufacturer and lot number not reported and 3 to 5 days post vaccination a similar eruption occurred in the same distribution (captured in case number 2010-02117). Also, between the 12 month and 18 month vaccinations the patient experienced two upper respiratory infections with fever, but without associated cutaneous eruptions. An ophthalmologic examination found no abnormalities. The reporters for this case are the same as for case 2010-02117. Documents held by sender: None.
Age: 1.0
Sex: F
Vaccine: DTAP, HIBV, MMR, PPV, DTAP
Symptoms: Pyrexia, Rash erythematous, Respiratory tract infection, Skin lesion, Upper respiratory tract infection
Clinical narrative: Abstract: "We report a female infant with recurrent biopsy-proven vesicobullous incontinentia pigmenti occurring after her 12-month and 18-month immunizations. To our knowledge, incontinentia pigmenti vesicobullous recurrence following immunizations has not been reported. We propose that vaccinations may serve as triggers for incontinentia pigmenti reactivation." Initial report received on 12 April 2010 from an article. A 12 month old female infant with a history of incontinentia pigmenti with recurrent vesicobullous eruptions, received an injection of HIB vaccine (manufacturer and lot number not reported), an injection of MMR (manufacturer and lot number not reported) and an injection of PNEUMO vaccine (manufacturer and lot number not reported) on an unspecified date. One week after the vaccinations, vesicobullous lesions appeared within linear patches. There were no verrucous lesions, fever or other systemic complaints. Medical history indicated the onset of seizures and rash started simultaneously at day 3 of life and the patient was hospitalized at 5 days old. On an unspecified date, a biopsy and histopathology had revealed IP and genetic testing confirmed the diagnosis. Vesicobullous eruptions recurred at one month after hospitalization and four months of age. The patient's mother had reported no eruptions following vaccinations at 2, 4 and 6 months. Of note, at 18 months of age, the patient received an injection of DTaP (manufacturer and lot number not reported and 3 to 5 days post vaccination a similar eruption occurred in the same distribution (captured in case number 2010-02117). Also, between the 12 month and 18 month vaccinations the patient experienced two upper respiratory infections with fever, but without associated cutaneous eruptions. An ophthalmologic examination found no abnormalities. The reporters for this case are the same as for case 2010-02117. Documents held by sender: None.
Age: 1.5
Sex: F
Vaccine: DTAP, HIBV, MMR, PPV, DTAP
Symptoms: Biopsy skin abnormal, Blood culture negative, Blood test normal, CSF culture negative, Condition aggravated
Clinical narrative: Initial report received on 12 April 2010 from an article. "We report a female infant with recurrent biopsy-proven vesicobullous incontinentia pigmenti occurring after her 12-month and 18-month immunizations. To our knowledge, incontinentia pigmenti vesicobullous recurrence following immunizations has not been reported. We propose that vaccinations may serve as triggers for incontinentia pigmenti reactivation." An 18-month-old female infant with a history of incontinentia pigmenti (IP) received an injection of DTaP (manufacturer and lot number not reported), on an unspecified date. Three to 5 days after vaccination, vesicobullous lesions appeared within the residual linear patches that corresponded to sites of previous lesions from earlier skin eruptions. There were no verrucous lesions, fever or other systemic complaints. An ophthalmologic examination found no abnormalities. The patient's medical history included seizure and a rash that simultaneously started on the patient's third day of life. At that time, the patient was treated with phenobarbital for new onset seizures. Rash was described as erythematous papules and vesicles and was initially diagnosed as erythema toxicum neonatorum. But the patient experienced vesicobullous eruptions again at one month and at four months of age and biopsy and genetic testing demonstrated a mutation in nuclear factor (NF) -kB essential modular (NEMO) which confirmed a diagnosis of IP. The patient's mother had reported no eruptions following vaccinations (unspecified) at 2, 4 and 6 months of age. However at 12 months of age, vesicobullous lesions appeared one week after receiving multiple vaccines including Hib VACCINE (manufacturer and lot number not reported). MMR (manufacturer and lot number not reported) and PNEUMO CONJUGATE VACCINE (manufacturer and lot number not reported). Between the 12 month and 18 month vaccinations, the patient experienced two upper respiratory infections with fever, but without associated cutaneous eruptions. The authors concluded that late reactivation of the vesicobullous stage of IP was triggered by immunizations that served to stimulate TNF-alpha activation. This case is linked to case 2010-02116 which describes the event that occurred at 12 months of age (same patient, same reporter). Documents held by sender: None.
Age: 1.5
Sex: F
Vaccine: DTAP, HIBV, MMR, PPV, DTAP
Symptoms: Congenital skin disorder, Convulsion, Culture urine negative, Dermatitis bullous, Electroencephalogram normal
Clinical narrative: Initial report received on 12 April 2010 from an article. "We report a female infant with recurrent biopsy-proven vesicobullous incontinentia pigmenti occurring after her 12-month and 18-month immunizations. To our knowledge, incontinentia pigmenti vesicobullous recurrence following immunizations has not been reported. We propose that vaccinations may serve as triggers for incontinentia pigmenti reactivation." An 18-month-old female infant with a history of incontinentia pigmenti (IP) received an injection of DTaP (manufacturer and lot number not reported), on an unspecified date. Three to 5 days after vaccination, vesicobullous lesions appeared within the residual linear patches that corresponded to sites of previous lesions from earlier skin eruptions. There were no verrucous lesions, fever or other systemic complaints. An ophthalmologic examination found no abnormalities. The patient's medical history included seizure and a rash that simultaneously started on the patient's third day of life. At that time, the patient was treated with phenobarbital for new onset seizures. Rash was described as erythematous papules and vesicles and was initially diagnosed as erythema toxicum neonatorum. But the patient experienced vesicobullous eruptions again at one month and at four months of age and biopsy and genetic testing demonstrated a mutation in nuclear factor (NF) -kB essential modular (NEMO) which confirmed a diagnosis of IP. The patient's mother had reported no eruptions following vaccinations (unspecified) at 2, 4 and 6 months of age. However at 12 months of age, vesicobullous lesions appeared one week after receiving multiple vaccines including Hib VACCINE (manufacturer and lot number not reported). MMR (manufacturer and lot number not reported) and PNEUMO CONJUGATE VACCINE (manufacturer and lot number not reported). Between the 12 month and 18 month vaccinations, the patient experienced two upper respiratory infections with fever, but without associated cutaneous eruptions. The authors concluded that late reactivation of the vesicobullous stage of IP was triggered by immunizations that served to stimulate TNF-alpha activation. This case is linked to case 2010-02116 which describes the event that occurred at 12 months of age (same patient, same reporter). Documents held by sender: None.
Age: 1.5
Sex: F
Vaccine: DTAP, HIBV, MMR, PPV, DTAP
Symptoms: Erythema toxicum neonatorum, Herpes simplex serology negative, No reaction on previous exposure to drug, Pyrexia, Skin oedema
Clinical narrative: Initial report received on 12 April 2010 from an article. "We report a female infant with recurrent biopsy-proven vesicobullous incontinentia pigmenti occurring after her 12-month and 18-month immunizations. To our knowledge, incontinentia pigmenti vesicobullous recurrence following immunizations has not been reported. We propose that vaccinations may serve as triggers for incontinentia pigmenti reactivation." An 18-month-old female infant with a history of incontinentia pigmenti (IP) received an injection of DTaP (manufacturer and lot number not reported), on an unspecified date. Three to 5 days after vaccination, vesicobullous lesions appeared within the residual linear patches that corresponded to sites of previous lesions from earlier skin eruptions. There were no verrucous lesions, fever or other systemic complaints. An ophthalmologic examination found no abnormalities. The patient's medical history included seizure and a rash that simultaneously started on the patient's third day of life. At that time, the patient was treated with phenobarbital for new onset seizures. Rash was described as erythematous papules and vesicles and was initially diagnosed as erythema toxicum neonatorum. But the patient experienced vesicobullous eruptions again at one month and at four months of age and biopsy and genetic testing demonstrated a mutation in nuclear factor (NF) -kB essential modular (NEMO) which confirmed a diagnosis of IP. The patient's mother had reported no eruptions following vaccinations (unspecified) at 2, 4 and 6 months of age. However at 12 months of age, vesicobullous lesions appeared one week after receiving multiple vaccines including Hib VACCINE (manufacturer and lot number not reported). MMR (manufacturer and lot number not reported) and PNEUMO CONJUGATE VACCINE (manufacturer and lot number not reported). Between the 12 month and 18 month vaccinations, the patient experienced two upper respiratory infections with fever, but without associated cutaneous eruptions. The authors concluded that late reactivation of the vesicobullous stage of IP was triggered by immunizations that served to stimulate TNF-alpha activation. This case is linked to case 2010-02116 which describes the event that occurred at 12 months of age (same patient, same reporter). Documents held by sender: None.
Age: 1.5
Sex: F
Vaccine: DTAP, HIBV, MMR, PPV, DTAP
Symptoms: Upper respiratory tract infection
Clinical narrative: Initial report received on 12 April 2010 from an article. "We report a female infant with recurrent biopsy-proven vesicobullous incontinentia pigmenti occurring after her 12-month and 18-month immunizations. To our knowledge, incontinentia pigmenti vesicobullous recurrence following immunizations has not been reported. We propose that vaccinations may serve as triggers for incontinentia pigmenti reactivation." An 18-month-old female infant with a history of incontinentia pigmenti (IP) received an injection of DTaP (manufacturer and lot number not reported), on an unspecified date. Three to 5 days after vaccination, vesicobullous lesions appeared within the residual linear patches that corresponded to sites of previous lesions from earlier skin eruptions. There were no verrucous lesions, fever or other systemic complaints. An ophthalmologic examination found no abnormalities. The patient's medical history included seizure and a rash that simultaneously started on the patient's third day of life. At that time, the patient was treated with phenobarbital for new onset seizures. Rash was described as erythematous papules and vesicles and was initially diagnosed as erythema toxicum neonatorum. But the patient experienced vesicobullous eruptions again at one month and at four months of age and biopsy and genetic testing demonstrated a mutation in nuclear factor (NF) -kB essential modular (NEMO) which confirmed a diagnosis of IP. The patient's mother had reported no eruptions following vaccinations (unspecified) at 2, 4 and 6 months of age. However at 12 months of age, vesicobullous lesions appeared one week after receiving multiple vaccines including Hib VACCINE (manufacturer and lot number not reported). MMR (manufacturer and lot number not reported) and PNEUMO CONJUGATE VACCINE (manufacturer and lot number not reported). Between the 12 month and 18 month vaccinations, the patient experienced two upper respiratory infections with fever, but without associated cutaneous eruptions. The authors concluded that late reactivation of the vesicobullous stage of IP was triggered by immunizations that served to stimulate TNF-alpha activation. This case is linked to case 2010-02116 which describes the event that occurred at 12 months of age (same patient, same reporter). Documents held by sender: None.
Age: 1.5
Sex: F
Vaccine: DTAP, HIBV, MMR, PPV, DTAP
Symptoms: Biopsy, Dermatitis bullous, Gene mutation identification test positive, Histology abnormal, Inappropriate schedule of drug administration
Clinical narrative: Initial report received on 12 April 2010 from an article. "We report a female infant with recurrent biopsy-proven vesicobullous incontinentia pigmenti occurring after her 12-month and 18-month immunizations. To our knowledge, incontinentia pigmenti vesicobullous recurrence following immunizations has not been reported. We propose that vaccinations may serve as triggers for incontinentia pigmenti reactivation." An 18-month-old female infant with a history of incontinentia pigmenti (IP) received an injection of DTaP (manufacturer and lot number not reported), on an unspecified date. Three to 5 days after vaccination, vesicobullous lesions appeared within the residual linear patches that corresponded to sites of previous lesions from earlier skin eruptions. There were no verrucous lesions, fever or other systemic complaints. An ophthalmologic examination found no abnormalities. The patient's medical history included seizure and a rash that simultaneously started on the patient's third day of life. At that time, the patient was treated with phenobarbital for new onset seizures. Rash was described as erythematous papules and vesicles and was initially diagnosed as erythema toxicum neonatorum. But the patient experienced vesicobullous eruptions again at one month and at four months of age and biopsy and genetic testing demonstrated a mutation in nuclear factor (NF) -kB essential modular (NEMO) which confirmed a diagnosis of IP. The patient's mother had reported no eruptions following vaccinations (unspecified) at 2, 4 and 6 months of age. However at 12 months of age, vesicobullous lesions appeared one week after receiving multiple vaccines including Hib VACCINE (manufacturer and lot number not reported). MMR (manufacturer and lot number not reported) and PNEUMO CONJUGATE VACCINE (manufacturer and lot number not reported). Between the 12 month and 18 month vaccinations, the patient experienced two upper respiratory infections with fever, but without associated cutaneous eruptions. The authors concluded that late reactivation of the vesicobullous stage of IP was triggered by immunizations that served to stimulate TNF-alpha activation. This case is linked to case 2010-02116 which describes the event that occurred at 12 months of age (same patient, same reporter). Documents held by sender: None.
Age: 1.5
Sex: F
Vaccine: DTAP, HIBV, MMR, PPV, DTAP
Symptoms: Interstitial lung disease, Pathology test, Pigmentation disorder, Pyrexia, Upper respiratory tract infection
Clinical narrative: Initial report received on 12 April 2010 from an article. "We report a female infant with recurrent biopsy-proven vesicobullous incontinentia pigmenti occurring after her 12-month and 18-month immunizations. To our knowledge, incontinentia pigmenti vesicobullous recurrence following immunizations has not been reported. We propose that vaccinations may serve as triggers for incontinentia pigmenti reactivation." An 18-month-old female infant with a history of incontinentia pigmenti (IP) received an injection of DTaP (manufacturer and lot number not reported), on an unspecified date. Three to 5 days after vaccination, vesicobullous lesions appeared within the residual linear patches that corresponded to sites of previous lesions from earlier skin eruptions. There were no verrucous lesions, fever or other systemic complaints. An ophthalmologic examination found no abnormalities. The patient's medical history included seizure and a rash that simultaneously started on the patient's third day of life. At that time, the patient was treated with phenobarbital for new onset seizures. Rash was described as erythematous papules and vesicles and was initially diagnosed as erythema toxicum neonatorum. But the patient experienced vesicobullous eruptions again at one month and at four months of age and biopsy and genetic testing demonstrated a mutation in nuclear factor (NF) -kB essential modular (NEMO) which confirmed a diagnosis of IP. The patient's mother had reported no eruptions following vaccinations (unspecified) at 2, 4 and 6 months of age. However at 12 months of age, vesicobullous lesions appeared one week after receiving multiple vaccines including Hib VACCINE (manufacturer and lot number not reported). MMR (manufacturer and lot number not reported) and PNEUMO CONJUGATE VACCINE (manufacturer and lot number not reported). Between the 12 month and 18 month vaccinations, the patient experienced two upper respiratory infections with fever, but without associated cutaneous eruptions. The authors concluded that late reactivation of the vesicobullous stage of IP was triggered by immunizations that served to stimulate TNF-alpha activation. This case is linked to case 2010-02116 which describes the event that occurred at 12 months of age (same patient, same reporter). Documents held by sender: None.